NCT05233696: Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least one site of disease amenable to radiation therapy
Exclusions: Patients with more than one prior line of chemotherapy in the locally advanced unresectable or metastatic setting; Patients with prior treatment with a taxane in the metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details

Comments are closed.

Up ↑